**A randomized, double-blind, placebo-controlled phase III study
evaluating olanzapine 5mg combined with standard antiemetic therapy
for the prevention of chemotherapy-induced nausea and vomiting
in patients receiving cisplatin-based hemotherapy.**

J-FORCE STUDY

J-SUPPORT and the Fourth agent “Olanzapine” Resist Cisplatin Emetogenesisity.

Kazuhisu Nakashima¹⁾, Takako Yanai²⁾, Masakazu Abe³⁾, Yasuyuki Hirashima³⁾, Haruyasu Murakami¹⁾, Satoshi Hamauchi⁴⁾, Hiroshi Ishikawa⁵⁾, Michiru Sakurai⁵⁾,
Takuhiro Yamaguchi⁶⁾, Sadamoto Zenda⁷⁾, Yosuke Uchitomi⁷⁾, Mikio Mori⁸⁾, Haruhiko Fukuda⁸⁾, Hiroyuki Terakado²⁾, Yuichiro Ohe⁹⁾, Satoru Iwasa¹⁰⁾, Hironobu Hashimoto²⁾

1) Department of Thoracic Oncology, Shizuoka Cancer Center, 2) Department of Pharmacy, National Cancer Center Hospital, 3) Department of Gynecologic Oncology, Shizuoka Cancer Center, 4) Department of Gastrointestinal Medical Oncology, Shizuoka Cancer Center, 5) Department of Pharmacy, Shizuoka Cancer Center, 6) Department of Biostatistics, Tohoku University Graduate School of Medicine, 7) Japan Supportive, Palliative and Psychosocial Oncology Group, 8) Japan Clinical Oncology Group Data Center, National Cancer Center, 9) Department of Thoracic Oncology, National Cancer Center Hospital, 10) Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital

Copyright © Japan Supportive, Palliative and Psychosocial Oncology Group. All rights reserved.

Background

Olanzapine (OLZ) is effective for chemotherapy-induced nausea and vomiting (CINV). Although 10mg of OLZ is widely used for CINV, patient sedation may be a concern.

In Japan, three phase II studies revealed the efficacy and safety of 5mg of OLZ combined with **palonosetron (PALO)**, **aprepitant (APR)**, and **dexamethasone (DEX)** for CINV induced by cisplatin-based chemotherapy.

In these studies, complete response (CR: no vomiting, no rescue) in the delayed phase (24-120h) was 83-95%. Compared with 10mg, 5mg of OLZ seemed to be equally effective and less sedative.

The aim of this phase III study is to evaluate the efficacy of 5 mg of OLZ as compared with placebo, in combination with APR, PALO, and DEX, for the control of CINV induced by cisplatin-based chemotherapy.

This multi-institutional phase III study is supported by **J-SUPPORT (Japan Supportive, Palliative and Psychosocial Oncology Group)** and **AMED (Japan Agency for Medical Research and Development)**.

This trial was registered in the UMIN Clinical Trials Registry as UMIN000024676 and began from February, 2017 in 30 institutes in Japan.

Phase II studies to examine **4-drug antiemetic regimen (PALO+APR+DEX +OLZ 5mg)** for cisplatin-based HEC in JAPAN.

Study	n	OLZ	CR rate	
			Acute phase	Delayed phase
TRIPLE study PALO+APR+DEX arm (Hashimoto et al. ASCO 2013, Suzuki et al. Ann Oncol 2016)	414 (Lung, GI, Neck)	–	92%	67%
Abe et al. (MASCC 2015, ESMO 2015 Support Care Cancer 2016)	40 (Gyne)	5mg (Day 0-5)	98%	95%
Nakashima et al. (MASCC 2016, JCO 2017)	30 (Lung)	5mg (Day 1-5)	100%	83%
Hashimoto, Yanai et al. (ASCO 2016, ICO 2017)	77 (Lung, GI, Neck)	5mg (Day 1-4)	99%	85%
	76 (Lung, GI, Neck)	10mg (Day 1-4)	100%	77%

randomized

Study Scheme

Primary endpoint is complete response rate in the delayed phase (24-120h).

We expect the delayed phase CR rate of the placebo and OLZ arms to be 65% and 75%, respectively. A total of **690 cisplatin-naïve patients** are required to achieve 80% power for a one-sided significance level of 0.025.

Study treatment

	Day 1	Day 2	Day 3	Day 4
OLZ / Placebo 2.5mg Capsule	2Cap	2Cap	2Cap	2Cap
PALO	0.75mg			
APR	125mg	80mg	80mg	
DEX	12mg	8mg	8mg	8mg
or				
FOS	150mg			
DEX	12mg	8mg	16mg	16mg

Evaluation of parameters

Endpoint	Acute 0-24h	Delayed 24-120h	Overall 0-120h
Complete response rate (no emesis, no rescue)	○	●	○
Complete control rate (no emesis, no rescue, and no more than mild nausea)	○	○	○
Total control rate (no emesis, no rescue, and no nausea)	○	○	○

- Time to treatment failure (i.e., time to first emetic episode or time to administration of rescue therapy, whichever occurred first).
- Severity of nausea.
- Severity of anorexia.
- Severity and influence to daily life of sleepiness.
- Adverse event.

● **Primary endpoint**

○ Secondary endpoint

Episodes of nausea and vomiting are recorded in a patient diary.

Blinding

Swedish orange capsules designed for double-blind clinical trials is used (Capsugel DBcaps®). Size D capsule which can fill 2.5mg was selected for this study because of easy to take.

OLZ capsule is filled with 1% Zyprexa® granule and placebo capsule is filled with lactose. Patients are randomly assigned to receive either a 5 mg OLZ dose or placebo on days 1–4, in combination APR (or fosaprepitant : FOS), PALO, and DEX.

Patients take 2 capsules (2.5mg x 2) orally after supper (around 19 o'clock).

Key eligibility criteria

Inclusion criteria

1. Receives the cisplatin ($\geq 50\text{mg}/\text{m}^2$)-based chemotherapy for the first time.
2. 20-75 years old at the enrollment.
3. ECOG performance status 0-2.
4. No symptomatic brain metastasis/carcinomatosis.
5. Not taking a medicine regularly, for example, 5HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, anti dopamine agonists, phenothiazine tranquilizers, antihistamine drugs, benzodiazepine agents, etc. within 48 hours prior to enrollment.

Exclusion criteria

1. In need of antiemetics at the enrollment.
2. Has diabetes mellitus with use of antidiabetics and has value measured HbA1c (NGSP) ≥ 6.5 or HbA1c (JDS) ≥ 6.1 at the enrollment.
3. Has symptomatic ascites that need therapeutic drainage.
4. Psychotic using antipsychotic drug.
5. Either received abdominal or pelvic irradiation within 6 days prior to enrollment or to receive abdominal or pelvic concurrent chemoradiotherapy.
6. Habitual smoker.

Recruitment

COI: We have no potential conflict of interest to disclose.